24/7 Market News Snapshot 06 May, 2025 – Tiziana Life Sciences Ltd. Common Shares (NASDAQ:TLSA)

May 6, 2025

DENVER, Colo., 06 May, 2025 (www.247marketnews.com) – (NASDAQ:TLSA) are discussed in this article.
Tiziana Life Sciences Ltd. is experiencing significant upward momentum in the market, with shares recently trading at $1.435, marking an impressive increase of approximately 17.62% from the previous closing price of $1.22. This surge reflects heightened investor interest, as evidenced by the current trading volume of 515.44K. As positive market sentiment surrounds the company, traders are advised to monitor technical indicators and resistance levels to assess the potential for further gains.

In conjunction with this market activity, the company has announced promising developments in its clinical research for intranasal foralumab, a pioneering treatment designed to target non-active secondary progressive multiple sclerosis (na-SPMS). The results from a recent open-label clinical trial have revealed significant improvements among participants, with all ten patients maintaining clinical stability in their Expanded Disability Status Scale (EDSS) scores after a minimum six-month treatment period. Notably, three out of four patients who extended their therapy for twelve months exhibited measurable improvements, underscoring the treatment’s potential efficacy in a patient population that historically has limited therapeutic options.

The study also noted a substantial reduction in fatigue for six out of the ten individuals, pointing to the therapy’s impactful role in enhancing quality of life. Complementing these clinical outcomes, TSPO-PET imaging indicated considerable decreases in microglial activation associated with MS pathology throughout the six-month treatment duration. Furthermore, notable adjustments in peripheral immune responses were detected, highlighting the unique therapeutic profile of intranasal foralumab that avoids common systemic side effects linked to intravenous medications.

Dr. Tanuja Chitnis, the principal investigator, emphasized the study’s transformative potential, suggesting that intranasal foralumab could significantly alter the management of immune dysregulation in progressive MS. As Tiziana Life Sciences pushes forward with its clinical initiatives, including an upcoming Phase 2 randomized trial, the company is poised to make a lasting impact on the treatment landscape for neuroinflammatory conditions.

Related news for (TLSA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.